Product
AAHI-SC3
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
THEMBA II T-CELL Vaccine: A Phase 1/2 Study of the Safety, Reactogenicity, and Immunogenicity of Vaccination With saRNA COVID-19 VaccinesStatus: Terminated, Estimated PCD: 2024-03-11